HCC - Subtypes, stratification and sorafenib

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 11, 2014, Pages 645-647

  Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR; PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADVANCED CANCER; CANCER PROGNOSIS; DISEASE SPECIFIC SURVIVAL; EGF GENE; GENE EXPRESSION; HEPATITIS B; HUMAN; KRT19 GENE; LIVER CELL CARCINOMA; LIVER NODULE; LIVER RESECTION; LIVER TRANSPLANTATION; NON INVASIVE MEASUREMENT; OVERALL SURVIVAL; REVIEW; SOMATIC MUTATION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; GENETICS; LIVER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84908551424     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.157     Document Type: Review

References (10)

1. Tanabe, K. K. et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299, 53-60 (2008).
2. Nault, J. C. et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4, 2218 (2013).
3. Hoshida, Y. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995-2004 (2008).
4. Nault, J. C. et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145, 176-187 (2013).
5. Govaere, O. et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut 63, 674-685 (2014).
6. Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73 (2006).
7. Forner, A. et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47, 97-104 (2008).
8. Memon, K. et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141, 526-535 (2011).
9. Mazzaferro, V. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10, 35-43 (2009).
10. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).